Galectin-9 in physiological and pathological conditions

被引:163
|
作者
Hirashima, M
Kashio, Y
Nishi, N
Yamauchi, A
Imaizumi, T
Kageshita, T
Saita, N
Nakamura, T
机构
[1] Kagawa Med Univ, Dept Immunol & Immunopathol, Miki, Kagawa 7610793, Japan
[2] Kagawa Med Univ, Dept Endocrinol, Miki, Kagawa 7610793, Japan
[3] Kagawa Med Univ, Dept Surg, Miki, Kagawa 7610793, Japan
[4] Hirosaki Univ, Sch Med, Inst brain Sci, Dept Vasc Biol, Hirosaki, Aomori 036, Japan
[5] Kumamoto Univ, Sch Med, Dept Dermatol, Kumamoto 860, Japan
[6] Kumamoto Univ, Sch Med, Dept Internal Med, Kumamoto 860, Japan
关键词
galectin-9 (Gal-9); eosinophil activation; cancer; apoptosis; prognosis;
D O I
10.1023/B:GLYC.0000014090.63206.2f
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We first cloned galectin-9 (Gal-9)/ecalectin as a T cell-derived eosinophil chemoattractant. Gal-9 plays a role in not only accumulation but also activation of eosinophils in experimental allergic models and human allergic patients, because Gal-9 induces eosinophil chemoattraction in vitro and in vivo and activates eosinophils in many aspects. Gal-9 requires divalent galactoside-binding activity but not the linker peptide of Gal-9 to exhibit its biological functions, and an unidentified matrix metalloproteinase is involved in the release of Gal-9. Our recent studies also showed that Gal-9 has other functions, such as cell differentiation, aggregation, adhesion, and death. Now, we and other groups are on the way of investigating the regulation and function of Gal-9 in a variety of physiological and pathological conditions. In this article, we will show the possible role of Gal-9 in physiological and pathological conditions by using our recent findings.
引用
收藏
页码:593 / 600
页数:8
相关论文
共 50 条
  • [1] Galectin-9 in physiological and pathological conditions
    Mitsuomi Hirashima
    Yumiko Kashio
    Nozomu Nishi
    Akira Yamauchi
    Tada-Atsu Imaizumi
    Toshiro Kageshita
    Naoki Saita
    Takanori Nakamura
    Glycoconjugate Journal, 2002, 19 : 593 - 600
  • [2] Galectin-9 in Gastroenterological Cancer
    Morishita, Asahiro
    Oura, Kyoko
    Tadokoro, Tomoko
    Shi, Tingting
    Fujita, Koji
    Tani, Joji
    Atsukawa, Masanori
    Masaki, Tsutomu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [3] Galectin-9: A Suppressor of Atherosclerosis?
    Yu, Jian
    Zhu, Ruirui
    Yu, Kuwu
    Wang, Yue
    Ding, Yan
    Zhong, Yucheng
    Zeng, Qiutang
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [4] Galectin-9 in Cancer Therapy
    Fujihara, Shintaro
    Mori, Hirohito
    Kobara, Hideki
    Rafiq, Kazi
    Niki, Toshiro
    Hirashima, Mitsuomi
    Masaki, Tsutomu
    RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2013, 7 (02) : 130 - 137
  • [5] Carbohydrate-recognition domains of galectin-9 are involved in intermolecular interaction with galectin-9 itself and other members of the galectin family
    Miyanishi, Nobumitsu
    Nishi, Nozomu
    Abe, Hiroko
    Kashio, Yumiko
    Shinonaga, Rika
    Nakakita, Shin-ichi
    Sumiyoshi, Wataru
    Yamauchi, Akira
    Nakamura, Takanori
    Hirashima, Mitsuomi
    Hirabayashi, Jun
    GLYCOBIOLOGY, 2007, 17 (04) : 423 - 432
  • [6] Galectin-9: a suppressor of food allergy?
    Sziksz, Erna
    Vannay, Adam
    Haczku, Angela
    ALLERGY, 2012, 67 (03) : 293 - 295
  • [7] A role for Galectin-9 in neutrophil trafficking
    Cooper, Dianne
    Iqbal, Asif J.
    Niki, Toshiro
    Hirashima, Mitsuomi
    Perretti, Mauro
    FASEB JOURNAL, 2012, 26
  • [8] Galectin-9 as a biomarker of disease severity
    Moar, Preeti
    Tandon, Ravi
    CELLULAR IMMUNOLOGY, 2021, 361
  • [9] GALECTIN-9: SWEETENING LEUKOCYTE RECRUITMENT
    Cooper, D.
    Iqbal, A. J.
    Niki, T.
    Hirashima, M.
    Perretti, M.
    INFLAMMATION RESEARCH, 2011, 60 : 87 - 88
  • [10] Association of galectin-9 with eosinophil apoptosis
    Saita, N
    Goto, E
    Yamamoto, T
    Cho, I
    Tsumori, K
    Kohrogi, H
    Maruo, K
    Ono, T
    Takeya, M
    Kashio, Y
    Nakamura, K
    Hirashima, M
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2002, 128 (01) : 42 - 50